Introduction
Thrombin, formed in the coagulation cascade, is a strong platelet activator. There are at least three receptors for thrombin on human platelets, PAR1, PAR4 and GPIbα. Both PARs belong to the seven transmembrane family of G-protein linked receptors and have been cloned and sequenced. Both are coupled to Gαq and Gα 12/13 [1] . Thrombin cleaves the receptors within the large N-terminal extracellular domain, creating new amino terminals, SFLLRN and GYPGQV respectively [2, 3] . The new N-terminus formed by thrombin cleavage serves as a "tethered ligand" [4] which binds intramolecularly and causes receptor activation. Specific agonist peptides, mimicking the new N-terminus, have been designed, for PAR1 the most often used is SFLLRN (PAR1-AP) [5] , for PAR4 the most potent is AYPGKF (PAR4-AP) [6] . If both cleavage sites are blocked by antibodies raised against peptides spanning the cleavage sites, the platelet response to thrombin is abolished [7] . It is known that, like other G protein-coupled receptors, PAR1 is quickly uncoupled from signalling and internalised, by sequestration into endosomes via coated pits, after activation by PAR1-AP [8] . In addition, there is some evidence that an additional way of PAR1 downregulation could occur by shedding into microparticles along with other integral membrane proteins [9] .
A polymorphism (-14 A/T) that affects PAR1 expression on the platelet surface has recently been identified. It has earlier been reported by Dupont et al. [10] that healthy volunteers showed a two-fold variation in receptor density which correlated with the exposure of platelet P-selectin and the aggregatory response induced by addition of PAR1-AP.
In this study we have used flow cytometry to measure the correlation between the number of PAR1 receptors per platelet and PAR1-AP induced platelet activation. In a portion of the samples, the number of PAR1 receptors was also measured after platelet activation with PAR1-AP, ADP, PAR4-AP or a collagen related peptide (CRP) to examine a possible decrease in receptor number indicating internalisation. We have also used ADP receptor 5 antagonists in order to remove the ADP-dependent part of the PAR1 response and examine whether this would improve the correlation between PAR1 receptor number and PAR1-AP induced platelet activation.
Materials and methods

Blood sampling
Venous blood was collected with minimal trauma from healthy adult volunteers donating blood at the local blood centre and from laboratory staff. In total there were 34 different female and 36 different male donors included. The age distribution was 44.6  13.5 years and 40.6  12.4 years, respectively. The blood donors were apparently healthy individuals, who had not ingested any drugs known to interfere with platelet function and without reported bleeding problems. They were informed about the purpose of the study and gave informed consent. The blood collection protocol was approved by the Ethics Committee at Linköping University Hospital.
Blood was collected by venipuncture and collected into 4.5 mL plastic vacuum tubes, S-
Lakes, NJ, USA) containing sodium citrate (final concentration 13 mmol/L). The blood was then kept at room temperature for a minimum of 30 minutes and maximum of 2 hours before use in any of the two studies. A sample tube with EDTA as anticoagulant (Vacutainer  ) was also collected for the determination of mean platelet volume, utilising the Cell-Dyn 4000 analysis system (Abbot Laboratories, Abbott Park, Illinois, USA).
Reagents
Chemicals used for the HEPES buffer (137 mmol/L NaCl, 2.7 mmol/L KCl, 1 mmol/L according to their instructions [11] . The peptide solution was diluted to 55 g/mL in 0.05% acetic acid and further diluted 1:4 in HEPES buffer upon thawing.
The antibodies were kept at +8C. All other solutions were portioned, kept at -70C and thawed in a water bath just before use. 
Flow cytometry
Measurements of PAR1 receptor number
In the second experiment, whole blood was diluted ( 
Statistics
Comparisons between groups were made using non-parametric tests, Wilcoxon Signed Ranks test (paired data) or Mann Whitney U Test (unpaired data). The correlations between receptor numbers and platelet activation responses or MPV were investigated using bivariate correlation analysis to calculate the Pearson correlation coefficients. The two-tailed significance of the correlations was also calculated. Data analysis was performed using SPSS for Windows (SPSS Inc., Chicago, IL, USA).
Results
Due to the fact that our initial trials indicated that there were considerable variations between duplicate samples, we performed all our measurements in duplicate. We found that the CV's for the imprecision within the duplicate samples were 25.7% for the negative control and 11.1% for the samples with the PAR1 antibody (n=75).
The PAR1 receptor number on resting platelets ranged from 547 to 2063 copies/platelet in the population examined (mean  S.D. 1276  320, n=70). The number did not differ between male and female donors (1281  278 in male and 1270  364 in female donors, respectively).
The mean platelet volume (MPV) was also determined and compared to the number of PAR1
receptors. There was a weak positive correlation between MPV and PAR1 receptor number, (r 2 = 0.08, p< 0.05, n=70) (see figure 1A) . As a comparison, a much higher correlation between MPV and the number of GPIb receptors was observed when this was investigated in a part of the population studied (r 2 = 0.22, p< 0.05, n=18) (figure 1B), but there was no significant correlation between PAR1 and GPIb receptor number (data not shown). Also, there were no significant correlations between MPV and PAR1-AP-induced fibrinogen binding or P-selectin expression (data not shown). The MPV did not differ between male and female donors (8.1  1.0 in male and 8.1  0.7 in female donors, respectively).
We found a strong correlation between platelet-bound fibrinogen and P-selectin expression, We also studied how activation of the platelets affected the number of PAR1 receptors. We found a significant decrease in PAR1 receptor number when platelets were exposed to PAR1-AP (37µmol/L), while activation with ADP (4.25µmol/L), PAR4-AP (5 mmol/L) or CRP (6.9 g/mL) significantly increased the number of PAR1 receptors ( figure 3 ). When the control with resting platelets from the same donor was set to 100%, the mean receptor number after activation with PAR1-AP was 71  19% (n=19), while activation with ADP, PAR4-AP and CRP gave mean receptor numbers of 151  27%, 120  21% and 138  25%, respectively (n= 11, 11 and 10, respectively). We also performed a control experiment where the samples were activated in the presence of the thrombin inhibitor hirudin, to ensure that the results were not 13 obscured by the formation of thrombin in the samples during activation. The PAR1 receptor numbers found in the presence and absence of hirudin did not differ for any of the platelet agonists (n=5-6, data not shown).
To check for eventual platelet aggregation during the activation of the samples, we also recorded the time needed for the analysis of 5000 platelets in the flow cytometer. When the time for the control with resting platelets from the same donor was set to 100%, the mean time for 5000 particles after activation with PAR1-AP was 113  16% (n=11), while activation with ADP, PAR4-AP and CRP gave mean times for 5000 particles of 112  11%, 97  16% and 124  17%, respectively (n= 11, 11 and 10, respectively). We also performed 67 of the individuals examined were also genotyped for the know polymorphism in the intervening sequence (IVSn)-14A/T, that has been previously coupled to PAR1 receptor expression [10] and increased response to PAR1-AP [10, 12] . In this material, we found 47
A/A homozygotes (70%), 18 A/T heterozygotes (27%) and 2 T/T homozygotes (3%). Figure   4 shows the distribution in PAR1 receptor number for the different genotypes. We also grouped the individuals into quartiles with regard to their platelet activation response (defined as percentage anti-fibrinogen binding platelets in response to PAR1-AP stimulation). This allowed us to group individuals even though they had been analysed using two different concentrations of PAR1-AP. The results are shown in figure 5 . Due to the difference in the number of individuals, we chose to group individuals with at least one T-allele into one group for the statistical analysis. However, there were no statistically significant differences in PAR1 receptor number or platelet reactivity between A/A individuals and the T/A or T/T individuals.
Discussion
In the population examined in this study, we found PAR1 receptor numbers ranging from 547
to 2063 with a mean of 1276 copies/platelet. This mean value was similar to that reported by Dupont et al. [10] , who used the same methods and reagents. However, the same authors found only a 2-fold variability in the PAR1 receptor number. A previous study with 125 Ithrombin found that there are approximately 50 high affinity binding sites/platelet and 1700 moderate affinity sites per platelet [13] . In subsequent experiments utilising radioiodinated monoclonal antibodies, directed towards the C-terminal of the cleavage site of the PAR1 receptor (NPNDKYEPF), the authors found the thrombin-binding sites to be 1800 sites per platelet [14, 15] . Thus there appears to be a good agreement between the numbers reported in different studies, the differences may be a reflection of the different methods used.
The flow cytometric method used by us and by Dupont et al. [10] offers several advantages for the determination of platelet receptor numbers. It is fast and relatively simple, and it makes it possible to determine the number of several different receptors at the same time, as long as there is a mouse antibody targeting the receptor available and that the receptor number is high enough to be detectable and to be covered by the calibration curve. However, in our hands we have seen that the variation between duplicate samples may be considerable, especially in samples with low fluorescence intensities; therefore we do not recommend the use of single samples, as is proposed by the manufacturers.
The PAR1 receptor expression level has been reported to be associated with an intronic polymorphism, intervening sequence (IVSn)-14A/T [10] . Individuals homozygous for the A allele also showed an increased response when activated by PAR1-AP [10, 12] . The genotyping of our population showed that the distribution of the A and T alleles were close to the one reported by Dupont et al. [10] , who found 74% A/A, 24% A/T and 2% T/T individuals in their French population. However, even though there seems to be a trend towards higher PAR1 receptor number and platelet reactivity in the A/A individuals in our study too, no statistically significant differences between A/A individuals and the T/A or T/T individuals were found. These findings lead to the conclusion that this polymorphism only explains a minor part of the individual variability in the number of PAR1 receptors observed in this study.
In contrast to the relatively strong correlation observed between mean platelet volume (MPV) and the number of the more abundant GPIb receptor, we only found a weak correlation between PAR1 receptor number and MPV, indicating that the platelet size is a comparably weak determinator of the number of PAR1 receptors. However, due to the individual variation in MPV, it is not fully correct to refer to the number of PAR1 receptors per platelet as "PAR1 density" (as commonly done) without measuring and correcting for individual differences in MPV.
In this study we looked at the correlation between PAR1 receptor number and PAR1-APinduced fibrinogen binding and P-selectin exposure, using flow cytometry. We found a significant correlation between the PAR1 receptor density, on resting platelets, and either of the two markers of platelet activation. The correlations were similar to the ones reported by Dupont et al. who analysed platelets activated by PAR1-AP (SFLLRN) using aggregometry and P-selectin expression using flow cytometry [10] . However, our correlation between PAR1
receptor number and fibrinogen binding determined using flow cytometry is higher than the correlation reported by them using aggregometry, indicating that the flow cytometric approach to determine platelet fibrinogen receptor activation is more precise; a fact that is also supported by comparative studies [16] . A difference between the studies is that Dupont et al. [10] only used male donors. We therefore analysed our material for sex-related differences, but could not find any parameter that differed between male and female donors.
Despite the significant correlation between PAR1 receptor density and platelet activation found here and elsewhere [10] , it is important to emphasise that other factors also affect the level of PAR1-mediated platelet activation. For example, Nylander et al. [17] achieved a 70% platelet inhibition during thrombin activation by blocking the ADP receptor P2Y 12 alone.
Furthermore, an individual difference in the platelet content of dense granules, which contain ADP, both before and after platelet activation by PAR1-AP, have been found. This will therefore indirectly affect the level of platelet activation via the PAR1 receptor [18] . In addition, the number of P2Y receptors per platelet and a range of other platelet agonists, such as adrenaline, collagen, lysophosphatidic acid, serotonin, thromboxane and platelet activating factor may also contribute to the PAR1-mediated platelet activation. Therefore we did a smaller study where we used ADP receptor antagonists to exclude the ADP component of the PAR1-AP induced response. However, this did not seem to improve the correlation between PAR1 receptor number and PAR1-AP induced activation response. To us, this was surprising, but the result highlights the fact that the relation between receptor activation and activation response is not easy to model and that many variables and unknown factors will affect the results.
To study the changes in PAR1 receptor number occurring after platelet activation, we activated platelets with PAR1-AP, PAR4-AP, ADP and a collagen related peptide (CRP). We found that the PAR1 receptor number decreased by approximately 30% upon activation with PAR1-AP, while activation with the other three agonists increased the number by 20-50%. In accordance with our results, internalisation of PAR1 receptors has been reported to occur also after activation by PAR1-AP, even though this process does not involve any proteolytic cleavage of the receptor [8, 9] . Molino et al. [9] found a 60% decrease after activation with PAR1-AP (SFLLRN, 100 μM) or thrombin (0.25 u/mL) and a 40% increase with ADP (10 μM) or U46619, a thromboxane A 2 analogue (10 μM), in a small number of samples (n = 3).
In addition, Dupont et al. [10] found a very small, but significant, decrease in PAR1 expression upon platelet activation by PAR1-AP (SFLLRN,100 μM) or collagen (100 μg/mL) (the mean decrease in receptor numbers was just around 100) and no significant change after activation with U46619 (10 μM). Since Dupont et al. [10] did all their activation experiments in the presence of a fibrinogen receptor antagonist, we hypothesised that this might have had some influence on their results, but in our hands, the presence of a fibrinogen receptor antagonist did not change the results markedly, and our counting experiments also verified that the formation of platelet aggregates was low and did not influence our results. The decrease in receptor number after activation with collagen that was reported by Dupont et al. [10] was not seen in our study, instead activation by CRP markedly increased the PAR1 number, just like ADP and PAR4-AP, supporting the suggestion by Molino et al. [9] that PAR1 receptors originally present in the surface connecting system of the platelet plasma membrane become accessible upon activation of platelet receptors other than PAR1.
Conclusion
In conclusion, this study shows a large variation in PAR1 receptor number in healthy individuals, a variation that is correlated to the platelet activation response, although there are 
